Analysts expect Agenus Inc (NASDAQ:AGEN) to announce ($0.28) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Agenus’ earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.27). Agenus posted earnings of ($0.35) per share during the same quarter last year, which would suggest a positive year over year growth rate of 20%. The business is expected to issue its next earnings report on Thursday, March 21st.
On average, analysts expect that Agenus will report full year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.35) to ($1.28). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.47) to ($1.33). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Agenus.
Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). The company had revenue of $12.80 million during the quarter, compared to analysts’ expectations of $10.76 million.
Shares of NASDAQ AGEN opened at $2.21 on Friday. Agenus has a 52-week low of $1.54 and a 52-week high of $6.19.
Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in Agenus during the second quarter worth $101,000. Virtu Financial LLC purchased a new stake in Agenus during the third quarter worth $105,000. Jefferies Group LLC lifted its holdings in Agenus by 171.2% during the third quarter. Jefferies Group LLC now owns 166,523 shares of the biotechnology company’s stock worth $356,000 after buying an additional 105,123 shares during the period. UBS Group AG lifted its holdings in Agenus by 1,180.3% during the first quarter. UBS Group AG now owns 137,417 shares of the biotechnology company’s stock worth $647,000 after buying an additional 126,684 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Agenus by 9.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 383,085 shares of the biotechnology company’s stock worth $870,000 after buying an additional 34,065 shares during the period. Institutional investors own 32.60% of the company’s stock.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Recommended Story: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.